Skip to main content
Logo DigiMed Bayern (Variante auf Weiß)
DigiMed Bayern

Funding of the Flagship Project “Digimed Bayern” Is Extended

Awards & Grants, EPI,

Helmholtz Munich has been participating in the DigiMed Bayern project of the Bavarian State Ministry of Health and Care (STMGP) since the end of 2018. The goal of the project is to advance digitized medicine in Bavaria. The project has now been extended and expanded until November 2024.

„DigiMed Bayern improves data-based and personalized medicine for cardiovascular diseases through so-called P4 medicine - predictive, preventive, personalized, participatory“, says Dr. Christian Gieger, Head of Research Unit Molecular Epidemiology (AME). Prof. Annette Peters, Director of the Institute of Epidemiology adds: „Our focus in DigiMed Bayern is on improving risk prediction and to this end we use long-term data and samples from the Bavarian population“. The results of the project have a positive impact on the people, this explains Dr. Holger Prokisch from the Institute of Neurogenomics: „Digitization in medicine enables comprehensive and efficient diagnosis and thus contributes to better care for patients and their families”.

Overall, the project under the leadership of the Deutsches Herzzentrum München (German Heart Center Munich) addresses the following sub-aspects:

  • Using coronary heart disease and stroke as examples, analyses of comprehensive data sets are carried out - here the Helmholtz researchers contribute expertise and results from the population study KORA Study, genetics and transcriptomics. All those involved in the healthcare system in Bavaria will benefit directly: risk prediction for coronary heart disease and stroke will become more accurate and preventive treatment will be facilitated. Initial results have already been obtained with the KORA study and are published. In the medium to long term, improvements in diagnosis and therapy are targeted. The population-wide identification of familial hypercholesterolemia as a serious exemplary risk factor for atherosclerosis is also to be improved sustainable.
  • In order to obtain a comprehensive picture of health and disease, DigiMed Bayern aims to cover and analyze the various genetic and molecular levels. To achieve this ambitious goal, state-of-the-art methods from genome analysis, proteomics and metabolomics are applied.
  • The technical, legal and social possibilities and limits of P4 medicine are recorded, advanced and documented. This includes a proactive exchange of information between all those involved in health.
  • The knowledge and structures gained are expandable in the healthcare system, research and industry and transferable to other diseases. In particular, work is underway to create an exemplary and transferable integrated digital infrastructure for medical data.
  • Bavaria is being further developed as a hub for P4 medicine. This is also reflected in international perception.

Further information

Work packages involving Helmholtz Munich:  

KORA Study


Dr. Christian Gieger, Head of Research Unit Molecular Epidemiology (AME) at Helmholtz Munich, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 4106 - E-Mail

Dr. Holger Prokisch, Institute of Neurogenomics at Helmholtz Munich, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2890 - E-Mail